ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma
O. M. Eichhoff, C. I. Stoffel, J. Kaesler, L. Briker, P. Turko, G. Karsai, N. Zila, V. Paulitschke, P. F. Cheng, A. Leitner, A. Bileck, N. Zamboni, A. Irmisch, Z. Balazs, A. Tastanova, , M. Levesque
The paper identifies ROS induction as a strategy to target MEK-inhibitor resistant NRAS-mutated melanoma cells by exploiting their quiescent metabolic state and elevated baseline ROS levels.
bioRxiv · Oct 19, 2022 · PreprintCancer Biology